342 related articles for article (PubMed ID: 10810933)
21. Taxane-based three-drug combination in metastatic and adjuvant treatment of breast cancer.
Nabholtz JM; Mackey J; Smylie M; Tonkin K
Semin Oncol; 1998 Oct; 25(5 Suppl 12):27-31. PubMed ID: 9865709
[TBL] [Abstract][Full Text] [Related]
22. Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations.
D'Incalci M; Schüller J; Colombo T; Zucchetti M; Riva A
Semin Oncol; 1998 Dec; 25(6 Suppl 13):16-20. PubMed ID: 9865687
[TBL] [Abstract][Full Text] [Related]
23. Review of docetaxel/doxorubicin combination in metastatic breast cancer.
Diéras V
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):31-3. PubMed ID: 9364539
[TBL] [Abstract][Full Text] [Related]
24. Docetaxel and anthracycline polychemotherapy in the treatment of breast cancer.
Nabholtz JM; Smylie M; Mackey J; Au HJ; Tonkin K; Au R; Morrish D; Salter E
Semin Oncol; 1999 Jun; 26(3 Suppl 8):47-52. PubMed ID: 10403474
[TBL] [Abstract][Full Text] [Related]
25. Future perspectives of docetaxel (Taxotere) in front-line therapy.
Piccart MJ; Di Leo A
Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-27-S10-33. PubMed ID: 9275004
[TBL] [Abstract][Full Text] [Related]
26. Taxanes in combination with doxorubicin in the treatment of metastatic breast cancer.
Dieras V
Semin Oncol; 1998 Oct; 25(5 Suppl 12):18-22. PubMed ID: 9865707
[TBL] [Abstract][Full Text] [Related]
27. Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin).
Burris HA
Semin Oncol; 2000 Apr; 27(2 Suppl 3):19-23. PubMed ID: 10810934
[TBL] [Abstract][Full Text] [Related]
28. Phase I-II studies of docetaxel as a single agent in the treatment of metastatic breast cancer.
Trudeau ME
Semin Oncol; 1999 Jun; 26(3 Suppl 8):21-6. PubMed ID: 10403470
[TBL] [Abstract][Full Text] [Related]
29. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
Chan S
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):19-24. PubMed ID: 9364537
[TBL] [Abstract][Full Text] [Related]
30. Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics.
Sparano JA
Semin Oncol; 1999 Jun; 26(3 Suppl 9):14-9. PubMed ID: 10426454
[TBL] [Abstract][Full Text] [Related]
31. Phase III randomized trials of docetaxel in patients with metastatic breast cancer.
Crown J
Semin Oncol; 1999 Jun; 26(3 Suppl 8):33-8. PubMed ID: 10403472
[TBL] [Abstract][Full Text] [Related]
32. Recently initiated studies: neoadjuvant treatments in the next century.
Gradishar WJ
Semin Oncol; 1999 Feb; 26(1 Suppl 3):26-9. PubMed ID: 10203268
[TBL] [Abstract][Full Text] [Related]
33. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
Alba E; Martín M; Ramos M; Adrover E; Balil A; Jara C; Barnadas A; Fernández-Aramburo A; Sánchez-Rovira P; Amenedo M; Casado A;
J Clin Oncol; 2004 Jul; 22(13):2587-93. PubMed ID: 15226326
[TBL] [Abstract][Full Text] [Related]
34. The current status of docetaxel for metastatic breast cancer.
Esteva FJ
Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):17-26. PubMed ID: 12108894
[TBL] [Abstract][Full Text] [Related]
35. Docetaxel (Taxotere): an overview of first-line monotherapy.
Trudeau ME
Semin Oncol; 1995 Dec; 22(6 Suppl 13):17-21. PubMed ID: 8604448
[TBL] [Abstract][Full Text] [Related]
36. Taxoids in combination with epirubicin: the search for improved outcomes in breast cancer.
Pagani O
Semin Oncol; 1998 Oct; 25(5 Suppl 12):23-6. PubMed ID: 9865708
[TBL] [Abstract][Full Text] [Related]
37. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
[TBL] [Abstract][Full Text] [Related]
38. Recent progress in the clinical development of docetaxel (Taxotere).
Hortobagyi GN
Semin Oncol; 1999 Jun; 26(3 Suppl 9):32-6. PubMed ID: 10426457
[TBL] [Abstract][Full Text] [Related]
39. Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer.
Nabholtz JM; Thuerlimann B; Bezwoda WR; Melnychuk D; Deschênes L; Douma J; Vandenberg TA; Rapoport B; Rosso R; Trillet-Lenoir V; Drbal J; Aapro MS; Alaki M; Murawsky M; Riva A
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):25-30. PubMed ID: 9364538
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
